EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kaempferol Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting TRIM56 to Regulate Lipid Metabolism

Hui Yang, Yingrui Wang, Lejian Zhu, Zhuoxi Chen, Shuo Yan, Yuan Du, Binsheng Wang, Leiming Zhang

International Journal of Molecular Sciences · 23.04.2026 · 27 (9) · 3767

DOI: 10.3390/ijms27093767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.04.2026. Verfasst von Hui Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Lipid Metabolism, Ubiquitin-Protein Ligases, Kaempferols. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic lipid accumulation and can progress to severe liver injury. Kaempferol (KPF), a plant-derived flavonoid, exhibits lipid-regulatory properties. Tripartite motif-containing protein 56 (TRIM56), an E3 ubiquitin ligase, has been reported to interact with fatty acid synthase (FASN) and limit hepatic lipogenesis. This study investigated whether KPF alleviates NAFLD through modulation of TRIM56-associated lipid metabolic pathways. Molecular docking, molecular dynamics simulations, and cellular thermal shift assays (CETSA) were employed to evaluate the interaction between KPF and TRIM56. High-fat diet-induced NAFLD mice and fatty acid-treated HepG2 cells were used to assess the effects of KPF on hepatic lipid accumulation. Histological analysis, lipid profiling, Oil Red O staining, Western blotting, immunofluorescence, and quantitative PCR were performed. Endogenous co-immunoprecipitation examined the association between TRIM56 and FASN, and siRNA-mediated knockdown of TRIM56 evaluated its functional contribution. KPF significantly reduced serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels, ameliorated hepatic steatosis in vivo, and decreased intracellular lipid accumulation in vitro. In silico and CETSA analyses supported the engagement of TRIM56 by KPF. KPF restored TRIM56 expression under steatotic conditions, whereas TRIM56 silencing attenuated its lipid-lowering effects. TRIM56 was confirmed to associate with FASN, and KPF treatment suppressed multiple lipogenic enzymes. These findings indicate that KPF alleviates hepatic steatosis, at least in part, through modulation of TRIM56-associated lipogenic pathways, highlighting TRIM56 as a potential therapeutic target in NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLipid MetabolismUbiquitin-Protein LigasesKaempferolsTripartite Motif ProteinsAnimalsHumansMiceHep G2 CellsDiet, High-FatMaleFatty Acid Synthase, Type IMice, Inbred C57BLLiverMolecular Docking SimulationLipogenesis

Stichwörter der Autor:innen

TRIM56fatty acid synthasekaempferollipid metabolismnon-alcoholic fatty liver disease

Substanzen

Ubiquitin-Protein LigasesKaempferolsTripartite Motif ProteinskaempferolFatty Acid Synthase, Type I

Autor:innen und Institutionen

  • School of Traditional Chinese Medicine, Shandong Medical and Pharmaceutical University, Yantai 264003, China.
  • Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, School of Pharmacy, Yantai University, Yantai 264005, China.

Förderung

  • Shandong Provincial Natural Science Foundation

Zitieren

APA

Yang, H., Wang, Y., Zhu, L., Chen, Z., Yan, S., Du, Y., Wang, B., & Zhang, L. (2026). Kaempferol Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting TRIM56 to Regulate Lipid Metabolism. International Journal of Molecular Sciences, 27(9), 3767. https://doi.org/10.3390/ijms27093767

Vancouver

Yang H, Wang Y, Zhu L, Chen Z, Yan S, Du Y, et al. Kaempferol Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting TRIM56 to Regulate Lipid Metabolism. International Journal of Molecular Sciences. 2026;27(9):3767. doi:10.3390/ijms27093767

BibTeX
@article{Yang2026,
  author = {Yang, Hui and Wang, Yingrui and Zhu, Lejian and Chen, Zhuoxi and Yan, Shuo and Du, Yuan and Wang, Binsheng and Zhang, Leiming},
  title = {Kaempferol Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting TRIM56 to Regulate Lipid Metabolism},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {3767},
  doi = {10.3390/ijms27093767}
}
Kostenlos starten →